Saracatinib

Drug Profile

Saracatinib

Alternative Names: AZD 0530; Saracatinib difumarate

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Baylor College of Medicine; Brigham and Women's Hospital; Loyola University Chicago; NHS National Services Scotland; Sheffield Teaching Hospitals NHS Foundation Trust; Stanford University; University of Cincinnati; University of Miami; University of South Florida; Yale University
  • Class Antineoplastics; Benzodioxoles; Quinazolines; Small molecules
  • Mechanism of Action Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Breast cancer; Cancer pain; Lymphangioleiomyomatosis
  • Phase I/II Prostate cancer
  • Phase I Alcoholism
  • Discontinued Bone cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 31 Mar 2017 AstraZeneca completes a phase II trial in Breast cancer (Combination therapy, Late-stage disease) in United Kingdom (PO) (ISRCTN23804370)
  • 03 Nov 2016 Yale University plans a phase II trial for Alcoholism (In volunteers) in USA (PO) (NCT02955186)
  • 01 Apr 2016 Phase-II clinical trials in Lymphangioleiomyomatosis in USA (PO) (NCT02737202)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top